Corporate Australia has warned against new tax rules that would require them to share new levels of global tax information publicly.
The biotechnology giant has downgraded its profit guidance after taking a blow from unfavourable currency movements as it competes for plasma donations.
The biotech giant says its $800 million vaccine production facility in Tullamarine will be running by 2026.
The Australian sharemarket fell on Tuesday as a fall in consumer confidence and the Reserve Bank’s determination to pin down inflation weighed on investor sentiment.
Telix Pharmaceuticals says it has the formula to be a big cash-generating biotech for the long term.
The blood plasma giant reaffirmed full-year guidance on Tuesday,though first-half profits saw a dip.
After a decade in the top job,CSL boss Paul Perreault weighs in on the future of mRNA,how Australia can secure a biotech boom - and how to choose an AFL team.
The biotech giant’s chief operating officer Paul McKenzie will start in the top job from March after Paul Perreault confirmed he will step down after a mammoth decade at the helm.
The biotech giant has amped up its plasma processing power in Victoria as it switches its focus back from COVID vaccines to specialist blood-based medicine.
Sleep treatments giant ResMed has been splashing cash on projects for growth as the sector spends up to secure post-pandemic growth.
The Aussie biotech giant will bring the first gene therapy for haemophilia B to market in the US,but the one-off treatment comes with a hefty price tag.